Goldstein David M 4

What Happened David M. Goldstein, Chief Scientific Officer of Alumis, was granted a derivative equity award on January 26, 2026 covering 216,675 shares. The Form 4 lists the acquisition as a derivative grant at $0.00 per share (no cash paid at grant). This is a compensation award (not an open-market purchase or sale) and does not reflect an immediate cash transaction.

Key Details

• Transaction date: 2026-01-26; Form 4 filed 2026-01-28 (appears timely under Form 4 rules).
• Award: 216,675 shares (derivative), reported price $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnote: 25% of the shares underlying this option vest on January 26, 2027; the remaining shares vest in equal monthly installments over the following 36 months, subject to continuous service and potential acceleration per the issuer’s 2024 Equity Incentive Plan.
• Filing accession: 0001751719-26-000003.

Context This filing reports a grant of equity compensation (an option-style award per the footnote). No shares were sold or bought on the open market and no immediate economic value was realized by the insider at grant. Such awards are common as part of executive compensation and indicate potential future ownership if vesting and any exercise conditions are met.